Investigation of Allegations of the Use of Mind-Altering Drugs to Facilitate
Total Page:16
File Type:pdf, Size:1020Kb
613CftBiT:Wi8F8Fl:.'i (U) Additional Information and Copies (U) To request copies of this report, contact tb)l6) \tllt 7 HC) at (703) 604ia (DSN 664..). (U) Suggestions for Audits and Evaluations (U) To suggest ideas for, or to request future audits and evaluations, contact the Office of the Deputy Inspector General for Intelligence at (703) 604-8800 (OSN 664-8800) or UNCLASSIFIED fax (703) 604-0045. Ideas and requests can also be mailed Lo: OLJ!G-INTEL (ATr'N: Intelligence Suggestions) Department of Defense Inspector General 400 Army Navy Drive (Room 703) Arlington, VA 22202-4704 hr\tI I \.I Acronyms and Abbreviations DIA Defense Intelligence Agency IV Intravenous J2 Joint Staff Litelligence Section JTF Joint Task Force JTf' GTMO Joint Task Force Guantanamo LSD Lysergic Acid Diethylamide OIG Office of the lnspector G e neral OSD Office of the Secretary of Defense USCENTCOM United States Central Command USSOUTHCOM United States Southern Command SECR:ETNFJ8F8RN BECltE5t\'i'NOF8R!:i INSPECTOR GENERAL DEPARTMENT OF DEFENSE ? 3 400 A.FHJY NAVY DRIVE ARLINGTON, VIRGINIA 22202-C7~ MEMORANDU M FOR UNDER SECR . ARY OF DEFENSE F R IN ELUGENCE DEPUTY A•• !STANT ECRETARY F DE FEN E FOR DETATNEE PO LI Y DIRECTOR . DEF SE INTEU.IGENCE AG NCY DEPUTY CHIEF OF STAFF G2. DEPARTMENT OF THE AR_\r1Y . 'JAVAL INSPECTOR GENERAL GENERAL COUNSEL, DEPARTMENT OF THE AIR FORCE fNSPECTOR GENERAL, U.S. SOUTHERi'l C MMAND fNSPECTOR GENERAL, U.S. JOINT F R E C O MMAND INSPECTOR GENERAL, U .. CENTRAL COMMAND INSPECTOR rEi ERAL, U.S. SPECIAi OP RAT IONS COMMAND FLEET JUDGE ADVOCATE, FLEET FORCES OM AND SUBJECT: lnvestigation of Allegations of th se of Mind -Altering Drug to Facilitate Interrogations of Detainees (Reporl No. 09-rNTEL-1J)(U) (U) We are providing tl11s report for your infom1ation and use. We performed !he in estigation in r pon e to a congre ~i onal inquiry. W e considered management comments on a draft of the report in preparing t linal report (U) Comments on the draft of this report conform ed to the requirement o DoD Directive 7650.3 and left no unresolved issues. Therefore, we do not require any additional comments. (U) We appreciate the courtesies extended to the taff Please direct qu lio n to me at (703) 604... DSN 664-IB or . (703) 604 -lm DSN 664 · . The team members are lis ted inside the back co er. ~ ---...... , ------- r:ih; ni( ~--- Deputy Inspector Cieneral for Intelligence SECRY.:T//N8r8ttP4 Sf. Ct~'Ff>'NO FOitM (1)) This page intentionally left blank SECR£TH?JOFOR.'1' Report No. 09-fNTEL-13 (Project No. D2007-DTNTO 1-0092.005) September 23, 2009 Results in Brief: Investigation of Allegations of the Use of Mind-Alteri ng Drugs to Facilitate Interrogations of Detainees (U) conditions) which could impair an (U) What We Did individual's ability to provide accurate information. We also observed that (U) In response to a tasking to the certain detainees, diagnosed as having Inspectors General of DoD and the serious mental health conditions and Central lntel Iigence Agency from being treated with psychoactive Senators Biden, Hagel, and Levin, we medications on a continuing basis, were investigated allegations that mind interrogated. altering drugs were administered to detainees to facilitate interrogation at DoD interrogation facilities. The (U) Client Comments and Central Intelligence Agency Inspector Our Response General conducted a separate investigation of its interrogation (U) Deputy Under Secretary of Defense facilities. for Human Intelligence, Counterintelligence and Security; (U) What We Found Di rector, Defense lntelligence Agency; Assistant Deputy Chlef of Sta ft~ (U) We did not substantiate allegations Depa1tment of theArmy, G2; Naval made by or on behalf of present and Inspector General; Inspector General, former detainees that tl1ey had been United States Southern Command; and administered mind-altering drugs for the Cl1ief of Staff, United States Joint interrogation purposes at DoD Forces Command concurred with our interrogation faci lities. findings. (U) We found no evidence that DoD (U) The Principal Director. Office of authorized the use of mind altering drugs Detainee Policy; General Counsel , to facilitate interrogation. Department of the Air Force; Chief of Staff, United States Central Command; (U//fOUOj We did, however, note that Deputy Director of Intelligence, United some detainees received ongoing States Special Operations Command, medication with psychoactive drugs (for and the Deputy Commander and Chief treatment ofdiagnosed medical of Staff, United States Fleet Forces Command had no comment on the draft repon. SISCR:Ji!FF:'/iNOF8Wi (U) This page intentionally left blank 8~CRET/~OEOI~ Table of Contents R esults in Brief In lrnduction Objective Background Scope and Methodology Prior Coverage Finding A. Administration of Mind-Altering Drugs Summary 2 Background 2 Res ults 3 Finding B. OSD Interrogation Policy as Pertains to Drugs Summary 9 Background 9 Resu lts 9 Appendix I. Published Reporls Review 11 Appendix II. - 14 Client Comments 19 Under Secretary of Defense for Intel Iigence 19 Under Secretary of Defense for Po licy 20 Defense Intel Iigence Agency 21 Department of the Anny . 22 Department of the "l\avy 23 Department of the Air Force 24 United States Southern Command 25 United States Joint Forces Command 26 United States Central Command 27 Un ited States Special Operations Command 28 United States Fleet Forces Command 29 SECRETh~J8F81Ui SEC1l£THNOFORN (U) This page intehtio!}ally left blank SECRETHN 0 F0 fl" -(U) Introduction {U) Objective (U) Th.is investigation was conducted to detennine the facrs sun-ounding repons that detainees and prisoners captured in Southwest Asia may have been administered rnind altering drngs to facilitate interrogation at DoD interrogation facilities. Other al legations or allegations based on incidents which occurred when the detainees were not under DoD control are not within the scope of this invt!stigation. (U) Background (U) On April 24, 2008, Senators Biden, Hagel, and Levin jointly signed a letter requesting that the lnspectors General of the DoD and Central Intelligence Agency investigate reports published in the news media that detainees had been administered mind-alteri ng drngs tofaci.litate interrogations. The Inspectors General mutually agreed to conduct the investigation withi n their respective agencies. (U) Scope and Methodology (U) We conducted this investigation from June 2008 through July 2009. Our investigation encompassed detainees under DoD control from September 200 l through April 2008. The investigative scope encompassed DoD detainee operations in Iraq, Afghanistan, Gua11tanarno Bay, and the United States. We conduclt!d on-site visits to detainee confinement facil ities at Guantanamo Bay and Charleston, South Carolina. We issued data calls to appropriate DoD components, reviewed repons published by government and non-governmental organizations, and inlerviewed individuals who we determined had information directly bearing on the matter. We believe that our analysis of the evidence obtained provides a reasonable basis for our findings and conclusions based on our investigative objectives. (U) Prior Coverage (lJ) We discovered no prior coverage specifically addressing the use of mind-altering drugs on detainees to faci litate interrogation during the last 5 years. However, for a review of related reports published by the U.S. Govemment, academic institutions, or human rights organizations, see Appendix I. 1 (U) We use tht: terms mind-a lleriog drugs, psychoactive drugs, and psychotropic drugs illterchangeably. We defined the terms to mean ::my chemical substance t h ~t alters brain functJon res ulting 1n changes in perception., mood, consciousness, anulor behavior. SECRFl'f/lPl0F0RN SECRET/I~\ OF6~4 (U) Finding A. Administration of Mind Altering Drugs (U) Summary. (U) We did not substantiate allegations made by or on behalf of present and fonner detainees that they had been administered mind-altering drugs for interrogation purposes while at DoD interrogation facilities. (U) Background. (U) For the pufl)oses or this investigation, we reviewed DoD documents including: relevant interrogation plans and logs, medical records and Behavioral Health Service reports.2 Additionally, we independent ly researched open source and classifi ed documents. We issued data calls for relevant infomrntion to 17 DoD organizations. We analyzed data received from all respondents and issued follow-up data calls to six OoD components. (U) We reviewed DoD interrogation policy from 2001 until 2008. This included a comprehensive review of the 2003 Office of the Secretary of Defense (OS D) Working Group3 review of interrogation techniques as well as actions taken by Joint Task Force 170.4 This review is further discussed in Finding 8. (U) We interviewed over 70 personnel related to our investigation. These individuals included six current or former Joint Task Force Guantanamo (JTF GTMO) Join t Intelligence Group Directors and Interrogation Control Element Chiefs, and four current or former Joint Medical Group Directors assigned to JT F GTMO between 200 I and 2008. We spoke with key personnel at JTF GTMO, United States Central Command (USCENTCOM), United States Southern Command (USSOUTHCOM). a11d United States Special Operations Command as well as the U.S. Naval Consolidated Brig in Charleston, South Carolina. We also interviewed detainees, legal counsel for detainees, and personnel involved in detention operations, interrogations and the medica l treatment of detainees.